Innate-immune crosstalk orchestrates T cell-mediated rejection in kidney transplants
-
By
-
Yuyun Hu
-
Zhiqiang Chen
-
Yujun Liang
-
Zhixuan Wu
-
Yijian Zhang
-
Junyu Guo
-
Chunqiang Dong
-
Guanmiao Chen
-
Michael Williams
-
Emily Johnson
-
Min He
-
Wei Du
-
Boqian Wang
-
July 7, 2026
-
Clinical Scorecard: Crosstalk in Innate Immunity Influences T Cell-Driven Rejection in Renal Transplants
At a Glance
| Category | Detail |
|---|
| Condition | T cell–mediated rejection (TCMR) |
| Key Mechanisms | Innate-adaptive immune crosstalk through chemokine and inflammatory networks. |
| Target Population | Kidney transplant recipients experiencing TCMR. |
| Care Setting | Transplant immunology and renal transplantation. |
Key Highlights
- TCMR is a major barrier to long-term kidney allograft survival.
- Single-cell RNA sequencing revealed distinct immune cell subsets involved in TCMR.
- DUSP1+ effector CD8+ T cells may be associated with graft injury.
- Innate immune cells enhance adaptive responses through chemokine signaling.
- Approximately 40% of TCMR patients respond poorly to standard therapies.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of TCMR should be confirmed through kidney biopsy.
Management
- Standard anti-rejection therapies are used for TCMR management.
Monitoring & Follow-up
- Long-term graft survival should be monitored in TCMR patients.
Risks
- Refractory or recurrent TCMR is associated with irreversible graft dysfunction.
Patient & Prescribing Data
Patients with end-stage renal disease undergoing kidney transplantation.
Standard anti-rejection therapies may not be effective for all TCMR patients.
Clinical Best Practices
- Utilize single-cell RNA sequencing for detailed immune profiling in TCMR.
- Focus on the immune microenvironment for understanding TCMR pathology.
Related Resources & Content
